Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous cytarabine during induction chemotherapy for de novo acute myeloid leukemia
ChiCTR-IPR-17012643Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission rate of induction chemotherapy. Started Feb 2015; status: recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IPR-17012643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012643.